AR022395A1 - PEPTIDOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFAvBETA6, LOS MEDICAMENTOS A BASE DE ESTOS PEPTIDOS, LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS PEPTIDOS, EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO, SECUENCIAS DE ADN RECOMBINANTE QUE CODIFICAN PARA UN FRA - Google Patents
PEPTIDOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFAvBETA6, LOS MEDICAMENTOS A BASE DE ESTOS PEPTIDOS, LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS PEPTIDOS, EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO, SECUENCIAS DE ADN RECOMBINANTE QUE CODIFICAN PARA UN FRAInfo
- Publication number
- AR022395A1 AR022395A1 ARP990106525A ARP990106525A AR022395A1 AR 022395 A1 AR022395 A1 AR 022395A1 AR P990106525 A ARP990106525 A AR P990106525A AR P990106525 A ARP990106525 A AR P990106525A AR 022395 A1 AR022395 A1 AR 022395A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptides
- prepare
- integrin
- formula
- leu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los péptidos de la formula (1) W1-X1n Arg X2 Asp Leu X3 X4 Leu X5 X6m-W2 en donde X1, X2, X3, X4, X5, X6 representan independientemente un resto deaminoácido, en el cual los aminoácidos se eligen independientemente del grupo formado por Ala, Asn, Asp, Arg, Cis, Gln, Glu, Gli, Fen, His lle, Leu, Lis, MetNle, homo-Fen, Fgli, Pro, Ser, Tr, Tri, Tir, o Val, y en el cual los aminoácidos mencionados también pueden estar derivados, W1 representa H o Ac, W2representa OH, OR, NHR, NR2 NH2, R representaalquilo de 1 a 6 átomos de C y n y m son independientemente un numero del 9 al 15. Un medicamento a base deestos péptidos que actua como inhibidor y permite combatir las enfermedades basadas en una expresion y funcion patologica de los receptores de integrinaAlfa v Beta6, en particular, la trombosis, el infarto de miocardio, las enfermedades cardíacas coronarias, la arteriosclerosis, los tumores, la osteoporosis,la fibrosis, las inflamaciones, las infecciones, la psoriasis, y también influye sobre los procesos curativos de cicatrizacion. El empleo de los péptidos deformula (1) para preparar un medicamento destinado a combatir las enfermedades mencionadas. Las composiciones farmacéuticas que contienen al menos unmedicamento a base de estospéptidos, junto con eventualmente excipientes y/o sustancias auxiliares y eventualmente también otras sustancias activas. El ADNrecombinante que contiene una secuencia que para codifica un fragmento peptídico que corresponde a un péptido de la formula (1).Un virus que contiene unaproteína de cápsula que presenta una secuencia que corresponde aun péptido de formula 1, y el empleo de este virus para preparar un medicamento destinadoa combatir las enfermedades basadas en una expresion y funcion patologica de los receptores de integrina alfav beta6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19858857 | 1998-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR022395A1 true AR022395A1 (es) | 2002-09-04 |
Family
ID=7891834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990106525A AR022395A1 (es) | 1998-12-19 | 1999-12-17 | PEPTIDOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFAvBETA6, LOS MEDICAMENTOS A BASE DE ESTOS PEPTIDOS, LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS PEPTIDOS, EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO, SECUENCIAS DE ADN RECOMBINANTE QUE CODIFICAN PARA UN FRA |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1140989A1 (es) |
| JP (1) | JP2002533064A (es) |
| CN (1) | CN1335853A (es) |
| AR (1) | AR022395A1 (es) |
| BR (1) | BR9916323A (es) |
| CA (1) | CA2355874A1 (es) |
| CZ (1) | CZ20012212A3 (es) |
| NO (1) | NO20013013L (es) |
| WO (1) | WO2000037487A1 (es) |
| ZA (1) | ZA200105929B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19929410A1 (de) * | 1999-06-26 | 2000-12-28 | Merck Patent Gmbh | Inhibitoren des Integrins avß6 |
| DE19933173A1 (de) * | 1999-07-15 | 2001-01-18 | Merck Patent Gmbh | Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶ |
| EP2287199B1 (en) | 2002-03-13 | 2017-08-02 | Biogen MA Inc. | Anti-alpha V beta 6 antibodies |
| KR20050102634A (ko) | 2003-02-06 | 2005-10-26 | 메르크 파텐트 게엠베하 | 펩티드성 설폰아미드 |
| CN104072614B (zh) | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
| GB0520068D0 (en) | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
| SG173364A1 (en) | 2006-07-10 | 2011-08-29 | Biogen Idec Inc | Compositions and methods for inhibiting growth of smad4-deficient cancers |
| WO2008112004A2 (en) | 2006-08-03 | 2008-09-18 | Astrazeneca Ab | ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF |
| AU2007354317A1 (en) * | 2006-10-19 | 2008-12-04 | Biogen Idec Ma Inc. | Treatment and prevention of chronic asthma using antagonists of integrin alphaVbeta6 |
| WO2009093251A2 (en) * | 2008-01-24 | 2009-07-30 | Gavish-Galilee Bio Applications Ltd | Reovirus vaccine based on sigma c protein sequence |
| WO2014007547A1 (en) * | 2012-07-03 | 2014-01-09 | Il Yang Pharm. Co.,Ltd. | Novel peptides and use thereof |
| US10035860B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
| WO2014144466A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
| RU2769702C2 (ru) | 2017-02-28 | 2022-04-05 | Морфик Терапьютик, Инк. | Ингибиторы интегрина avb6 |
| EP3589285A4 (en) | 2017-02-28 | 2020-08-12 | Morphic Therapeutic, Inc. | INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6) |
| EP3617206A1 (en) | 2018-08-29 | 2020-03-04 | Morphic Therapeutic, Inc. | Integrin inhibitors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ219515A (en) * | 1987-02-10 | 1989-09-27 | Wellcome Found | Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope |
-
1999
- 1999-12-11 CA CA002355874A patent/CA2355874A1/en not_active Abandoned
- 1999-12-11 EP EP99963507A patent/EP1140989A1/de not_active Withdrawn
- 1999-12-11 JP JP2000589556A patent/JP2002533064A/ja active Pending
- 1999-12-11 CZ CZ20012212A patent/CZ20012212A3/cs unknown
- 1999-12-11 BR BR9916323-3A patent/BR9916323A/pt not_active IP Right Cessation
- 1999-12-11 CN CN99814760A patent/CN1335853A/zh active Pending
- 1999-12-11 WO PCT/EP1999/009842 patent/WO2000037487A1/de not_active Application Discontinuation
- 1999-12-17 AR ARP990106525A patent/AR022395A1/es not_active Application Discontinuation
-
2001
- 2001-06-18 NO NO20013013A patent/NO20013013L/no not_active Application Discontinuation
- 2001-07-18 ZA ZA200105929A patent/ZA200105929B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20012212A3 (cs) | 2001-09-12 |
| WO2000037487A1 (de) | 2000-06-29 |
| CA2355874A1 (en) | 2000-06-29 |
| ZA200105929B (en) | 2003-03-18 |
| NO20013013D0 (no) | 2001-06-18 |
| BR9916323A (pt) | 2001-10-30 |
| WO2000037487A8 (de) | 2001-03-29 |
| CN1335853A (zh) | 2002-02-13 |
| NO20013013L (no) | 2001-06-18 |
| JP2002533064A (ja) | 2002-10-08 |
| EP1140989A1 (de) | 2001-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR022395A1 (es) | PEPTIDOS QUE ACTUAN COMO INHIBIDORES DE LA INTEGRINA ALFAvBETA6, LOS MEDICAMENTOS A BASE DE ESTOS PEPTIDOS, LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN AL MENOS UNO DE ESTOS PEPTIDOS, EL EMPLEO DE ESTOS PEPTIDOS PARA PREPARAR UN MEDICAMENTO, SECUENCIAS DE ADN RECOMBINANTE QUE CODIFICAN PARA UN FRA | |
| Chorev et al. | Recent developments in retro peptides and proteins—an ongoing topochemical exploration | |
| ES2346771T3 (es) | Peptidos con multiples dominios a-helicoidales anfipaticos y procedimientos para su uso. | |
| ES2271950T3 (es) | Peptidos y peptidomimeticos con similitud estructural a p53 humana que activan la funcion p53. | |
| ES2359616T3 (es) | Péptidos citotóxicos modificados por restos voluminosos o lipofílicos. | |
| DK0950096T3 (da) | Anti-invasive og anti-angiogene urokinase-fragmenter og deres anvendelse | |
| ES2544573T3 (es) | Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor | |
| ES2406090T3 (es) | Péptidos que tienen actividad farmacológica para tratar los trastornos asociados con la alteración de la migración celular, tal como el cáncer | |
| RU95115239A (ru) | Аналог эритропоэтина | |
| EA021222B1 (ru) | Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro | |
| ES2427171T3 (es) | Tratamiento de infecciones fúngicas y/o protistas | |
| BRPI0207502B1 (pt) | compostos, enanciômeros, composição farmacêutica, uso de compostos, e, processo para a fabricação de compostos | |
| UY23561A1 (es) | Procedimiento para la preparacion de tnf-muteinas | |
| EA011037B1 (ru) | Олигомерные пептиды и их применение для лечения вич инфекций | |
| ES2227639T3 (es) | Sintesis de analogos de pth y ptrp. | |
| AR003121A1 (es) | Antagonistas del receptor de adhesión, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y su empleo para preparar medicamentos y combatir enfermedades | |
| ES2323963T3 (es) | Peptido y/o proteinas y su uso para la fabricacion de un medicamento terapeutico y/o preventivo. | |
| PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
| ES2322228T3 (es) | Metodos de preparacion de peptidos. | |
| JP2011523634A (ja) | ペプチド、ペプチド模倣物およびそれらの誘導体、それらの製造、ならびに治療および／または予防活性のある医薬組成物を調製するためのそれらの使用 | |
| US20080171697A1 (en) | Peptides Having For Example Antiangiogenic Activity and Applications Thereof In Therapeutics | |
| DE69508382D1 (de) | Peptomere mit erhöhter immunogenizität | |
| AR029629A1 (es) | Cefaiboles, nuevos antiparasitos obtenidos a partir de acremonium tubaki, procedimiento para su preparacion composiciones farmaceuticas y procedimiento para su preparacion y utilizacion de los mismos para preparar un medicamento. | |
| AR020101A1 (es) | Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado. | |
| JP2018526987A (ja) | 腫瘍抑制ペプチド |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |